Epizyme + 20 Stocks Moving In Monday’s Pre-Market Session
Gainers
Tenax Therapeutics, Inc. (NASDAQ: TENX) rose 90.1% to $0.59 in pre-market trading after dipping more than 46% on Friday.
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
40 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash.
67 Biggest Movers From Yesterday
Gainers
Convey Health Solutions Holdings, Inc. (NYSE: CNVY) shares jumped 138.4% to close at $10.30 as the company agreed to be taken private by TPG Capital.
71 Biggest Movers From Yesterday
Gainers
Sidus Space, Inc. (NASDAQ: SIDU) shares jumped 225% to close at $4.68 on Wednesday after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
Sorrento’s Scilex Initiates Phase 2 Study To Evaluate Safety And Efficacy Of SP-103 In Subjects With Acute Low Back Pain
Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% in
Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer
The FDA has signed off Sorrento Therapeutics Inc’s (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK…
Sorrento’s License Partner Lee’s Pharm Announces Full Enrollment Of 498 Patients In A Phase III Trial Of Socazolimab For First-Line Treatment Of Extensive-Stage Small-Cell Lung Cancer
Sorrento's License Partner, Lee's Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Sorrento Therapeutics shares are trading high following FDA clearance of IND for Abivertinib in metastatic castrate resistant prostate cancer (mCRPC)
Sorrento Therapeutics, Inc. (NASDAQ: SRNE) received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug application (IND) of Abivertinib (Fujovee) for patients with metastatic castrate resistant prostate cancer (mCRPC) in the Phase 2 MAVERICK clinical study.
Sorrento Announces FDA Authorization To Proceed With Phase 2 Study Of Abivertinib To Treat Metastatic Castrate Resistant Prostate Cancer
Sorrento Announces FDA Authorization to Proceed With Phase 2 Study of Abivertinib (Fujovee™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)
FDA granted IND clearance for Abivertinib